How do DIR fees and PBM clawbacks hit pharmacy revenue after the claim pays?

Since January 1, 2024, Medicare Part D has not allowed a plan to take pharmacy price concessions back months after the claim pays. Most pages on DIR fees still miss that. The money did not stop leaving: it moved into the counter price for Part D, and into true-ups, performance fees, audit recoupments and refund timing everywhere else. This page traces each one to its line on the remittance.

What are DIR fees, and why do pharmacies call them PBM clawbacks?

DIR fees are price concessions a pharmacy benefit manager collects from a pharmacy outside the original claim payment, and pharmacies call them clawbacks because, until 2024, most were taken weeks or months after the claim had already paid. DIR stands for direct and indirect remuneration, a Medicare Part D reporting category for every payment that changes what a plan sponsor ultimately spends on a drug. Most DIR dollars are manufacturer rebates. The slice that lands on pharmacies is the price concessions their network contracts require them to give back.

CMS’s own figures show how fast total DIR grew before reform: from $8.7 billion in 2010 to $23.6 billion in 2015, rising from 11.3% to 17.2% of gross Part D drug cost. Those totals include manufacturer rebates, so they overstate what pharmacies paid, and pages quoting them as pharmacy fees misread the data.

Pharmacy DIR fees explained: flat, percentage and performance fees

Pharmacy DIR fees came in three shapes. A flat fee took a fixed dollar amount per claim. A percentage fee took a share of the ingredient cost, which is why specialty pharmacies, dispensing high-cost drugs, felt them most. A performance fee moved with how the pharmacy scored on plan measures such as adherence and generic dispensing, and it was settled only after the measurement period closed. That last type made a paid claim unpredictable, because nobody knew the final reimbursement on the day the prescription left the counter.

What did DIR fee reform change in 2024, and what did it leave alone?

DIR fee reform moved every Part D pharmacy price concession onto the claim itself, effective January 1, 2024. CMS finalized the change in rule CMS-4192-F, published in the Federal Register on May 9, 2022, and redefined the negotiated price in 42 CFR 423.100 as the lowest amount a network pharmacy can receive in total for a particular drug. If a concession can reduce what the pharmacy is paid, it now has to be inside the price at adjudication, in every phase of the benefit.

The rule changed who pays as well as when. CMS estimated it would reduce beneficiary costs by $26.5 billion from 2024 to 2032, add $46.8 billion to government Part D costs and save manufacturers about $16.8 billion over the same period.

Three things sit outside the rule. It covers Medicare Part D only, so commercial plans and Medicaid managed care keep whatever their contracts and state law allow. It does not stop money flowing to a pharmacy after the claim: CMS told plans in a November 2023 memo that performance payments made to pharmacies after the sale must be reported as negative DIR, so upward adjustments still exist. And it does not touch audits, which recover money for claim errors rather than as price concessions. Prompt pay rules also stayed in place, with Part D plans required to pay clean electronic claims from most network pharmacies within 14 days under 42 CFR 423.520.

Why 2024 was the hardest year

The switch created a double hit. In 2024, pharmacies took the new, lower Part D prices at the counter while plans were still collecting retroactive fees owed on 2023 claims. An NCPA survey of independent owners in February 2024 found 32% were considering closing that year, 85% said the overlap threatened their viability and 42% had taken a line of credit to cover it. The lesson still applies to every fee that remains: a deduction you cannot see on the claim has to be reserved for before it arrives.

Where does pharmacy revenue still leave after the claim pays in 2026?

In 2026, money leaves a pharmacy after payment through five channels, and the 2024 rule fixed only the Part D price concession part of one of them. In our pharmacy billing reviews, post-adjudication reductions equaled 2.6% of paid pharmacy dollars. Effective rate true-ups made up 38% of post-payment reductions, commercial and Medicaid performance fees 29%, audit recoupments 21% and MFP refund gaps 12%.

Effective rate true-ups

An effective rate contract guarantees the pharmacy an average reimbursement across a basket of claims, usually all generics or all brands, written as a discount off average wholesale price. The PBM pays each claim at whatever rate it sets during the year, then compares the total against the guarantee. If it paid more than promised, it takes the difference back in one reconciliation, often months after the period ends. The true-up arrives as a single provider-level deduction rather than a claim adjustment, which is why it is the hardest clawback to trace and the largest one in our data.

Commercial and Medicaid managed care performance fees

The performance fees that left Part D are still written into many commercial and Medicaid managed care pharmacy contracts, tied to the same adherence and generic dispensing measures. Some states restrict them. Texas bars a state-regulated plan or PBM from reducing a pharmacy claim after adjudication through aggregated effective rates, quality programs or other remuneration fees, except through an audit, and a contract cannot waive that protection. It applies to state-regulated plans only, so the same pharmacy can be protected on one card and exposed on the next.

Audit recoupments

A PBM audit can take back money on claims that paid long ago, on the grounds that the claim was billed or documented wrong. Unlike a fee, an audit finding is about the record, and most of it is preventable. Days supply errors drove 34% of audit recoupment dollars in our claim audit, ahead of missing prescriber or prescription details at 22%, refills billed early at 17%, quantity mismatches at 15% and signature log gaps at 12%.

Findings are worth contesting. Appeals filed by Luxen were overturned 68% of the time across our clients, yet 19% of denied claims were never reworked or appealed in the average practice we reviewed. Audit letters left on a desk follow the same pattern, and the response window is usually short.

Medicare negotiated drug refunds

The newest gap began on January 1, 2026, when negotiated maximum fair prices for the first 10 Medicare drugs took effect. The Part D plan pays the pharmacy at the negotiated price, and the manufacturer owes the pharmacy a refund for the difference, by default the wholesale acquisition cost minus the maximum fair price, times the quantity. Plans send claim data to the Medicare Transaction Facilitator, and manufacturers then have a 14-day window to pay. Across our pharmacy clients, MFP refunds arrived a median 26 days after dispensing, and 6% of MFP drug claims had no matching refund after 30 days.

Copay clawbacks

A copay clawback happens when the patient’s copay is higher than the plan’s total reimbursement for the drug and the PBM recovers the difference from the pharmacy, usually by netting it out of a later payment. The remit then shows a smaller payment than the counter receipt implied.

What does a clawback cost on a single claim?

A single post-payment fee can remove most of the margin on a generic claim, and the annual total for a mid-sized independent runs into six figures. Take an independent community pharmacy filling 6,000 prescriptions a month, 80% of them generics, and receiving $520,000 a month from PBMs.

The $3.25 fee cuts the margin by 71%, and nothing on the claim warned anyone.

The effective rate true-up works on the whole year. Say the pharmacy’s generics carry $3.2 million in average wholesale price over the year, and the PBM paid them at an average of AWP minus 83.5%, or $528,000. The contract guarantees AWP minus 85%, or $480,000. The PBM takes back the $48,000 difference. Spread across 57,600 generic claims, that is about $0.83 a claim, all of it collected in one deduction.

The negotiated drug refund is a float rather than a loss. If the pharmacy fills one negotiated drug 40 times a month with a wholesale acquisition cost of $560 and a maximum fair price of $250, each fill carries a $310 refund, or $12,400 a month owed by the manufacturer. Because refunds arrive weeks after dispensing, roughly a month of refunds is always outstanding, and every refund that never arrives is $310 someone has to chase.

Applied to all receipts, 2.6% of $520,000 is $13,520 a month, or $162,240 a year. None of it shows as a denial. Every claim paid.

How do you find DIR fees and clawbacks on an 835 remittance?

You find them by reconciling each PBM remittance line by line, because post-payment deductions sit in different places from claim payments and rarely carry a prescription number.

1. Reconcile remits, not deposits. The bank deposit is the net of claim payments and deductions. Start from the 835 remittance file each PBM sends, which lists both.
2. Split claim-level adjustments from provider-level ones. Adjustments tied to one claim sit with that claim. True-ups, fees and recoupments usually sit in the PLB segment at the end of the file, with a reason code such as WO for overpayment recovery and a reference number instead of a prescription number.
3. Get the detail behind every PLB line. Request the PBM’s claim-level report for each provider-level deduction. In our reviews, 41% of PLB adjustments could not be matched to a claim without that report.
4. Match negotiated drug refunds claim by claim. Refund records from the Medicare Transaction Facilitator carry remark code N909 when the standard default refund formula was used. Match each refund to its dispensing claim and list every claim with no refund after 30 days.
5. Check each deduction against the contract. Confirm the rate, the measurement period, and whether state law allows that deduction for that plan type.
6. Dispute inside the contract window. Most network agreements set a short window to contest a reconciliation or an audit finding. A missed deadline turns a recoverable amount into a write-off.
7. Reserve every month. Book an accrual for expected true-ups and fees so the reconciliation month does not read as a loss. 14 of 19 pharmacies booked no reserve for true-ups in our reviews.

The same discipline catches underpayments. On the claims we audit across specialties, underpayments against contracted rates appeared on 7.8% of paid claims, and the average underpaid claim was short by $38. Our denials and AR recovery team works those gaps by payer rather than one remit at a time.

What mistakes make clawbacks worse?

• Assuming the 2024 rule ended all clawbacks and stopping reconciliation of commercial and Medicaid managed care remits.
• Booking revenue at the adjudicated amount with no reserve, which turns every reconciliation month into a surprise.
• Signing network amendments without reading the fee schedules. In our 2026 survey, 44% could not name the fee basis in their current billing contract.
• Treating a PBM audit letter as final. Findings can be appealed, and the window is short.
• Waiting on negotiated drug refunds without matching them, so a missing refund looks like a slow one.
• Assigning nobody. 42% of practice managers said nobody owns denial follow-up full time, and post-payment reconciliation usually sits further down the list.

Should a pharmacy reconcile clawbacks in house or outsource it?

Keep reconciliation in house if one person already reads every remittance each week and knows each PBM contract, and outsource it when deductions post as lump sums that nobody traces. Fully loaded in-house billing cost 7.9% of collections for practices under $2M, across 96 practices that shared payroll data with us, while outsourced billing typically runs 3% to 6% of collections. On the worked example, 2.6% of PBM receipts is $162,240 a year.

Pharmacies that also bill Part B drugs, supplies and vaccines carry a second set of remits on the medical side, covered on our pharmacy billing services page, and the front end of the drug revenue cycle, from benefit investigation to underpayment recovery, is on our pharmacy revenue cycle management page. Our full-service medical billing runs that medical side inside the system you already use. If you are comparing partners, start with our guide to choosing a medical billing company, or send us your remits through a free billing review.

DIR fees vs true-ups vs audit recoupments vs negotiated drug refunds: how do they compare?

Each post-payment mechanism hits at a different time, shows up in a different place on the remit and is contested a different way, so the first job is naming which one you are looking at.

DIR fees and PBM clawbacks are a pharmacy benefit problem. Dental, physical therapy, behavioral health, ambulance and primary care practices bill the medical benefit and never see them; their version of the leak is contract underpayments and payer recoupments.

Independent community pharmacies

Independents carry the most Part D exposure relative to size. In the NCPA February 2024 survey, 51% said Part D was 40% or more of their business, and more than half lost money on over 60% of their Part D prescriptions after the switch. Their post-payment risk now sits mostly in commercial and Medicaid managed care true-ups and performance fees, plus audit findings on days supply. The key control is a monthly match of every provider-level deduction to claim detail.

Specialty pharmacies

Percentage-based fees always hit specialty hardest because a share of a high ingredient cost is a large dollar amount. The market is also concentrated: the FTC found that pharmacies affiliated with the three largest PBMs took about 68% of specialty drug dispensing revenue in 2023, up from 54% in 2016, which leaves unaffiliated specialty pharmacies little bargaining power on contract terms. See our oncology billing page for the medical benefit side of the same drugs.

Long-term care pharmacies

Long-term care pharmacies sit outside the Part D 14-day prompt pay rule, so their baseline payment timing is already slower than retail. CMS names long-term care pharmacies among those that may have material cash flow concerns under negotiated drug pricing when refunds lag on drugs dispensed to whole facilities. Our skilled nursing facility billing page covers the facility side of those residents.

Home infusion pharmacies

Home infusion splits one episode across Part B, Part D and commercial plans, with drug, supply and nursing lines on different claims. A post-payment deduction on the pharmacy benefit can therefore sit against a drug whose administration was billed and paid on the medical side, and matching the two is the reconciliation work. Our infusion billing page covers the medical claim lines.

Health system and 340B contract pharmacies

Contract pharmacies dispensing 340B drugs face reconciliation on two fronts: the PBM remit and the covered entity’s split-billing report. CMS lists 340B covered entities among the dispensers that may have material cash flow concerns under negotiated drug pricing, because refund timing interacts with 340B acquisition cost. Our research on 340B modifier payment covers how the Part B side is identified on the claim.